Amplifying the impact of early cancer detection.

Qurin is a pioneering diagnostic biotech company committed to unlocking the full potential of early cancer detection by enhancing test usability and diagnostic precision.

Contact

Liquid biopsy: Promising but challenges remain

Despite the promise of new liquid biopsy techniques, most tests currently aren’t accurate enough for reliable detection of early-stage cancers. False positives can lead to unnecessary medical procedures and anxiety, while false negatives risk providing false reassurance, delaying critical, life-saving treatments.

Our innovative approach

Qurin has developed a non-invasive, patented sample collection and biomarker extraction technology that amplifies cancer signals for improved detection. This breakthrough enables the discovery of novel biomarkers while maximizing the utility of existing ones and integrating seamlessly into existing workflows. As a result, Qurin is uniquely positioned to deliver highly accurate, user-friendly cancer tests that facilitate early treatment and save lives.

We’re currently focused on validating our platform for early detection of bladder cancer from urine, whilst we grow our pipeline of potential applications.

Amplifying the impact of early cancer detection.

Reducing the burden of disease on patients and healthcare systems.

Qurin is a pioneering diagnostic biotech company committed to realizing the full potential of early cancer detection—identifying cancer when treatments are most effective and less costly.

Cancer detection saves lives

The sooner cancer is detected, the better the chances of survival—and the lower the costs.

The survival probability drops significantly when cancer is detected at late stages. At these stages, surgery becomes far less effective, radiotherapy is often necessary, and chemotherapeutic drugs are more toxic. Treatment and care costs also increase substantially for cancers discovered at later stages.

How we amplify impact

While historically the focus has purely been on detecting the cancer signal, we augment this by ensuring there is a cancer signal to detect in the first place — this represents the critical first step in any diagnostic test. Our patented sampling and pre-concentration approach has the potential to dramatically increase the adoption and accuracy of diagnostic testing, amplifying the impact of existing and novel biomarkers.

Team

Qurin is an ambitious biotech startup bringing together a wide range of technical, executive and operational expertises. We’re located in the heart of the vibrant Bio Science Park in Leiden as part of a growing ecosystem. Our team is supported by world-class experts to ensure success at every stap of the way.

Early cancer detection saves lives and reduces healthcare costs.

Survival rates across 11 cancer types (bladder, female breast, colorectal, esophagus, kidney, liver and intrahepatic bile duct, lung and bronchus, ovary, pancreas, prostate and stomach).

Cancer related costs associated with the first 12 months averaged over 11 cancer types (bladder, breast, colorectal, esophagus, kidney, liver, lung, ovary, pancreas, prostate and stomach.

Connal et al, JOTM, 2023

Realizing the full potential of early cancer detection

We envision a future where early detection is user-friendly, accurate, and convenient—empowering clinicians to make informed decisions and reducing the burden of disease on patients and healthcare systems.

At Qurin, we are committed to optimizing every aspect of early cancer detection. Central to our approach is the often-overlooked yet critical step of sample collection—the foundation of any cancer detection test. By centering our design philosophy on the individual, we ensure the sample collection process is as seamless and patient-friendly as possible. Our patented technology ensures the strongest possible cancer signal is captured, enabling us to develop highly accurate and transformative diagnostic tests.

Translating Our Vision Into Real-World Impact

Qurin’s approach is both orthogonal and complementary to existing efforts in early cancer detection. By amplifying biomarker signals by orders of magnitude, we maximize the utility of existing biomarkers while uncovering novel ones.

This breakthrough enables the development of highly accurate and user-friendly early cancer diagnostic tests. Our initial focus is on bladder cancer due to its high prevalence and the significant unmet need for early detection. Building on this foundation, we aim to create a robust pipeline of oncology diagnostics, targeting cancers where early detection offers the greatest clinical and economic impact.

Beyond oncology, our biomarker extraction and pre-concentration technologies have broad potential to enhance both novel and existing molecular diagnostic tests. We are actively partnering with researchers to help amplify the impact of their diagnostic innovations.

Amplifying every step of early cancer detection.

Our urine-based platform transforms early cancer diagnostics by amplifying usability for patients and laboratories. We’re on track to make cancer testing 10x easier to perform, yield 10x more biomarkers, and 10x easier to process in the lab. Collectively this realizes orders of magnitude more impactful cancer detection.

We are a science-driven organization at the intersection of engineering, nanotechnology, biochemistry, genetics, and biology. Qurin has developed a patented approach for point-of-care urinary sample collection, biomarker extraction, and pre-concentration. Our innovative workflow is designed with automation in mind and integrates with widely accessible analytical tools, such as PCR. This end-to-end approach eliminates the need to compromise between test accuracy and usability, delivering robust and practical diagnostic solutions.

Do you want to amplify your impact?

We’ re always excited to connect with talented and passionate individuals who share our vision for the future.

If you're enthusiastic about contributing to innovative diagnostics and making a difference in the field of early cancer detection, we encourage you to submit an open application. Please send your resume and cover letter to recruitment@qurin.com, highlighting your skills and areas of interest.

Additionally, we recommend checking this page regularly or following us on LinkedIn to stay updated on future opportunities. We carefully review all applications and will reach out if a role aligns with your expertise and passion.

Latest news

Qurin Signs USD 2.3M Subcontract in ARPA-H’s Prestigious POSEIDON Cancer Screening Program

28/10/2025

Qurin signed a subcontract with the prime awardee, Owlstone Medical, launching a partnership that also includes MIT, Boston University, Georgia Tech Research Corporation, and Planned Systems International, Inc. Leiden (Netherlands), October 28, 2025: Qurin, a research and development company specializing in cell(-free) DNA capture from urine and molecular assays for early disease detection, announces […]

Board members

Marc Peeters

As the former CEO of Antwerp University Hospital and a specialist in gastrointestinal oncology, Marc Peeters brings extensive clinical and executive experience to Qurin. With both an MD and PhD, he led the hospital’s Oncology Department until 2021 and served as CEO through the end of 2024. His long-standing involvement with Qurin, initially as chair of the one-tier board and now in a more operational role, reflects his deep commitment to advancing non-invasive cancer diagnostics through urine-based screening technologies.

Otto Paul Brand

Mr. Brand has spent over three decades in the finance sector, leading Brand Boekhouders from 2017. His experience spans accounting for local businesses to bespoke services for international corporations.

Roderik Kraaijenhagen

As Dutch cardiologist and healthcare entrepreneur with a PhD in vascular medicine from Amsterdam University Medical Center (AUMC), Roderik Kraaijenhagen combines clinical expertise with entrepreneurship in preventive healthcare and digital innovation. His work focuses on early diagnostics, prevention, longevity and empowering patients through self-management, using advanced technologies and personalized approaches.

Gijs Lipsch

Gijs Lipsch is a seasoned investment management professional based in Amsterdam, Netherlands, with over 30 years of experience in the financial sector. He holds leadership and partner roles at several organizations, including Wealth Management Partners NV (WMP), where he serves as an Asset Manager and Partner, advising families, foundations, and associations on asset management with a focus on private equity. Lipsch has previously held senior positions at top institutions such as Merrill Lynch and IBS Capital Management, where he worked in investment management and advisory roles. He is also actively involved in several non-profit activities, serving as a board member (Bestuurslid) for organizations like Stichting Romo Foundation and Stichting Bob Pinedo Cancer Care Award.

Board Advisor

David Reinhoudt

Renowned for his work at the University of Twente, harnesses his deep knowledge of nanotechnology. His role in the project is invaluable as he offers insights from his significant discoveries, particularly those related to potential cancer research applications.

Piet Schalkwijk

Has vast experience in change management, conflict management (mediation), international business structures, and intellectual property. He offers comprehensive advice on governance issues, organizational change, intellectual property matters and strategic decision-making.”

Evert-Jan Zondag

Evert-Jan has built a long-standing career in the financial sector since starting at ABN Amro in 1995. Since then, he has worked at the Royal Bank of Scotland Group in structured finance and at Deutsche Bank as a Managing Director in Hong Kong. He is currently a director at Romo Invest, the family office of the Onderdijk family, where he is responsible for all investments. In addition, Evert-Jan is involved with the Romo Foundation.